BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 19024623)

  • 21. Are there unintended consequences of step-therapy programs?
    Cox ER; Seiz BJ
    Am J Manag Care; 2009 Sep; 15(9):654, 656; author reply 656. PubMed ID: 19747030
    [No Abstract]   [Full Text] [Related]  

  • 22. Public health value of fixed-dose combinations in hypertension.
    Ruilope LM; Burnier M; Muszbek N; Brown RE; Keskinaslan A; Ferber P; Harms G
    Blood Press Suppl; 2008 Jun; 1():5-14. PubMed ID: 18705530
    [TBL] [Abstract][Full Text] [Related]  

  • 23. NIH promotes use of lower cost drugs for hypertension.
    Spurgeon D
    BMJ; 2004 Mar; 328(7439):539. PubMed ID: 15001483
    [No Abstract]   [Full Text] [Related]  

  • 24. Relative costs of antihypertensive drug treatment.
    Strasser T
    J Hum Hypertens; 1992 Dec; 6(6):489-94. PubMed ID: 1296015
    [No Abstract]   [Full Text] [Related]  

  • 25. [Medical economics of antihypertensive agents].
    Yamazaki T
    Nihon Rinsho; 2006 Aug; 64 Suppl 6():285-8. PubMed ID: 16981557
    [No Abstract]   [Full Text] [Related]  

  • 26. Cost considerations in the drug treatment of hypertension. Is older better?
    Kaplan NM
    Pharmacoeconomics; 1996 Apr; 9(4):283-5. PubMed ID: 10160102
    [No Abstract]   [Full Text] [Related]  

  • 27. [Discontinuation of subsidizing of certain antihypertensive agents is not well thought-out].
    Berggren B; Lindström T; Nyström F; Cizinsky S; Weiss L; Willenheimer R
    Lakartidningen; 2008 Aug 27-Sep 2; 105(35):2345-6. PubMed ID: 18831442
    [No Abstract]   [Full Text] [Related]  

  • 28. The cost of treating high blood pressure in general practice in France.
    Tibi-Levy Y; de Pouvourville G; Westerloppe J; Bamberger M
    Eur J Health Econ; 2008 Aug; 9(3):229-36. PubMed ID: 17566802
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Out-of-pocket costs to users: medicine options for hypertension.
    Arredondo A
    Am J Hypertens; 2008 May; 21(5):492. PubMed ID: 18437138
    [No Abstract]   [Full Text] [Related]  

  • 30. [Pharmacoeconomic aspects of the treatment of essential hypertension].
    Martynov AI; Giliarevskiĭ SR; Ostroumova OD; Nesterova MV; Mamaev VI
    Ter Arkh; 2001; 73(9):82-8. PubMed ID: 11642090
    [No Abstract]   [Full Text] [Related]  

  • 31. Blood-pressure-related disease is a global health priority.
    Macmahon S; Alderman MH; Lindholm LH; Liu L; Sanchez RA; Seedat YK
    J Hypertens; 2008 Oct; 26(10):2071-2. PubMed ID: 18806633
    [No Abstract]   [Full Text] [Related]  

  • 32. Community attributable risk: its economic dimensions.
    Wilhelmsen L
    J Hum Hypertens; 1992 Dec; 6(6):469-72. PubMed ID: 1296011
    [No Abstract]   [Full Text] [Related]  

  • 33. Pharmacoeconomic evaluation of a pharmacist-managed hypertension clinic.
    Caro JJ; Lee K
    Curr Hypertens Rep; 2002 Dec; 4(6):418. PubMed ID: 12419167
    [No Abstract]   [Full Text] [Related]  

  • 34. [Antihypertensive treatment. Benefits and costs].
    Jensen HA; Svendsen TL
    Ugeskr Laeger; 1993 Jan; 155(2):118-20. PubMed ID: 8421861
    [No Abstract]   [Full Text] [Related]  

  • 35. Cost effective analyses in the treatment of high blood pressure.
    Fletcher A
    J Hum Hypertens; 1992 Dec; 6(6):437-45. PubMed ID: 1296007
    [No Abstract]   [Full Text] [Related]  

  • 36. [Investigation and treatment of primary hypertension].
    Lindstedt I; Nilsson PM
    Lakartidningen; 2008 Jul 23-Aug 5; 105(30-31):2107-12. PubMed ID: 18751450
    [No Abstract]   [Full Text] [Related]  

  • 37. [Decisions by the state, county council's money and my patient. Consequences of the LFN survey of antihypertensive agents].
    André M; Andersén-Karlsson E; Landahl S; Löfmark R; Silfverhielm B; Skoglund I
    Lakartidningen; 2008 May 21-27; 105(21):1549-50. PubMed ID: 18574990
    [No Abstract]   [Full Text] [Related]  

  • 38. [The comparative assessment of the efficacy of hypotensive preparations in stage-II hypertension].
    Tiurin VP; Fursov AN; Gospodarenko AL; Liapkova NB; Orlov FA
    Voen Med Zh; 1997 Nov; 318(11):46-7. PubMed ID: 9461836
    [No Abstract]   [Full Text] [Related]  

  • 39. The treatment of hypertension in Canada: are we making progress?
    McAlister FA
    CMAJ; 1999 Sep; 161(6):713-4. PubMed ID: 10513278
    [No Abstract]   [Full Text] [Related]  

  • 40. Considerations in the treatment of mild-to-moderate hypertension.
    Giaquinta D
    Manag Care Interface; 2001 Mar; 14(3):80-1. PubMed ID: 11301960
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.